Company’s 36-month beta value is -0.18.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATXI is 1.36M, and currently, short sellers hold a 2.32% ratio of that floaft. The average trading volume of ATXI on October 18, 2024 was 44.93K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATXI) stock’s latest price update
The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) has dropped by -6.13 compared to previous close of 2.12. Despite this, the company has seen a fall of -1.49% in its stock price over the last five trading days. globenewswire.com reported 2024-10-09 that MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
ATXI’s Market Performance
ATXI’s stock has fallen by -1.49% in the past week, with a monthly drop of -26.30% and a quarterly drop of -42.32%. The volatility ratio for the week is 15.10% while the volatility levels for the last 30 days are 10.68% for Avenue Therapeutics Inc The simple moving average for the past 20 days is -9.82% for ATXI’s stock, with a -69.09% simple moving average for the past 200 days.
ATXI Trading at -20.57% from the 50-Day Moving Average
After a stumble in the market that brought ATXI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.65% of loss for the given period.
Volatility was left at 10.68%, however, over the last 30 days, the volatility rate increased by 15.10%, as shares sank -23.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.96% lower at present.
During the last 5 trading sessions, ATXI fell by -1.49%, which changed the moving average for the period of 200-days by -83.42% in comparison to the 20-day moving average, which settled at $2.21. In addition, Avenue Therapeutics Inc saw -83.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATXI starting from KRANZLER JAY D, who purchase 497 shares at the price of $2.50 back on Sep 30 ’24. After this action, KRANZLER JAY D now owns 620 shares of Avenue Therapeutics Inc, valued at $1,242 using the latest closing price.
KRANZLER JAY D, the Director of Avenue Therapeutics Inc, purchase 3 shares at $2.40 during a trade that took place back on Sep 27 ’24, which means that KRANZLER JAY D is holding 123 shares at $7 based on the most recent closing price.
Stock Fundamentals for ATXI
The total capital return value is set at -2.8. Equity return is now at value -1037.72, with -311.39 for asset returns.
Currently, EBITDA for the company is 4.16 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.30.
Conclusion
In a nutshell, Avenue Therapeutics Inc (ATXI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
